Pembrolizumab - Merck & Co

Drug Profile

Pembrolizumab - Merck & Co

Alternative Names: Anti-PD-1 monoclonal antibody - Merck; Humanised monoclonal IgG4 antibody against PD-1 - Merck; Keytruda; Lambrolizumab; MK-3475; SCH-900475

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; The Leukemia & Lymphoma Society
  • Developer Aduro BioTech; Amgen; Augusta University; BerGenBio; Big Ten Cancer Research Consortium; BioLineRx; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; DNAtrix; Eisai Co Ltd; Eli Lilly; Emory University; Exelixis; Fox Chase Cancer Center; Genexine; Gilead Sciences; Hoosier Cancer Research Network; Icahn School of Medicine at Mount Sinai; ImmunoGen; Incyte Corporation; Institute of Cancer Research; M. D. Anderson Cancer Center; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (France); National Cancer Institute (USA); Netherlands Cancer Institute; Northwestern University; NYU Langone Medical Center; Oslo University Hospital; Plexxikon; Providence Health & Services; Sarcoma Alliance for Research through Collaboration; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Spanish Breast Cancer Research Group; TG Therapeutics Inc; University Health Network; University of Alabama; University of Birmingham; University of California at San Francisco; University of California, San Diego; University of Pittsburgh; Verastem; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Registered Gastric cancer
  • Phase III Breast cancer; Gastrointestinal cancer; Hepatocellular carcinoma; Liver cancer; Mesothelioma; Multiple myeloma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Adenocarcinoma; Bladder cancer; Bone cancer; Brain metastases; Cholangiocarcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Inflammatory breast cancer; Lymphoma; Meningioma; Merkel cell carcinoma; Myelodysplastic syndromes; Nasopharyngeal cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Penile cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Thymoma; Thyroid cancer
  • Phase I/II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; T cell lymphoma
  • Phase I Haematological malignancies
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 27 Nov 2017 Massachusetts General Hospital and Merck initiates enrolment in a phase II trial for Metastatic Melanoma (Inoperable/Unresectable, Combination therapy, Metastatic disease) in USA (NCT03149029)
  • 27 Nov 2017 Bayer and Merck plan a phase I trial for Hepatocellular carcinoma (Combination therapy, First-line therapy) in Germany in May 2018 (NCT03347292)
  • 17 Nov 2017 Merck initiates enrolment in a phase II trial in Neuroendocrine tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03290079)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top